Reasons for daratumumab initiation
| . | DMT (n = 72) . |
|---|---|
| Increasing dFLC, n (%) | 42 (58) |
| dFLC at daratumumab initiation, median (IQR), mg/dL | 3.95 (2.1-10.3) |
| Meeting criteria for >50% increase from nadir and dFLC > 2 mg/dL, n | 30 |
| Meeting Pavia high-risk dFLC progression criteria,20 n | 20 |
| Meeting ISA progression criteria,14 n | 14 |
| Insufficient response to prior therapy, n (%) | 17 (24) |
| dFLC at daratumumab initiation, median (IQR), mg/dL | 8.47 (3.1-20.2) |
| Continued or worsening organ dysfunction, n (%) | 6 (8) |
| Intolerance to prior therapy, n (%) | 7 (10) |
| . | DMT (n = 72) . |
|---|---|
| Increasing dFLC, n (%) | 42 (58) |
| dFLC at daratumumab initiation, median (IQR), mg/dL | 3.95 (2.1-10.3) |
| Meeting criteria for >50% increase from nadir and dFLC > 2 mg/dL, n | 30 |
| Meeting Pavia high-risk dFLC progression criteria,20 n | 20 |
| Meeting ISA progression criteria,14 n | 14 |
| Insufficient response to prior therapy, n (%) | 17 (24) |
| dFLC at daratumumab initiation, median (IQR), mg/dL | 8.47 (3.1-20.2) |
| Continued or worsening organ dysfunction, n (%) | 6 (8) |
| Intolerance to prior therapy, n (%) | 7 (10) |
ISA, International Symposium of Amyloid and Amyloidosis.